Matt DeLisa
Direktor/Vorstandsmitglied bei Versatope Therapeutics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Christopher Locher | M | - |
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | - |
Dave Putnam | M | - |
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | - |
Brenda McCabe | F | - |
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | 5 Jahre |
Jeremy Gowler | M | 47 |
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | 3 Jahre |
Salim Yazji | M | 55 |
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | 5 Jahre |
Jim Kuo | M | - |
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 6 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Matt DeLisa
- Persönliches Netzwerk